Table 2.
Baseline Patient Characteristics Before and After Propensity Score Adjustment
| Variable | No prophylaxis (N = 2,577) |
Prophylaxis (N = 648) |
Abs. SMD | No prophylaxis | Prophylaxis | Abs. SMD |
|---|---|---|---|---|---|---|
| Crudea | Crudea | Crude | Adjusted | Adjusted | Adjusted | |
| Age (years) | 59.1 | 61.25 | 0.156 | 59.58 | 60.22 | 0.047 |
| Sex (proportion female) | 1074 (41.7%) | 247 (38.1%) | 0.073 | 41% | 41.9% | 0.017 |
| Deprivation index | 2.84 | 2.84 | 0.004 | 2.84 | 2.79 | 0.038 |
| Elixhauser comorbidity index | 2.15 | 2.49 | 0.088 | 2.23 | 2.24 | 0.003 |
| Histology | ||||||
| Glioblastoma | 1957 (75.9%) | 483 (74.5%) | 0.032 | 75.6% | 75% | 0.014 |
| Diffuse astrocytoma | 126 (4.89%) | 33 (5.09%) | 0.009 | 5% | 5.3% | 0.014 |
| Anaplastic astrocytoma | 230 (8.93%) | 43 (6.64%) | 0.092 | 8.5% | 8.8% | 0.011 |
| Oligodendroglioma | 53 (2.06%) | 19 (2.93%) | 0.052 | 2.2% | 2.3% | 0.003 |
| Anaplastic oligodendroglioma | 115 (4.46%) | 23 (3.55%) | 0.049 | 4.3% | 4.2% | 0.003 |
| Unspecified glioma | 96 (3.73%) | 47 (7.25%) | 0.136 | 4.4% | 4.4% | 0.001 |
| Extent of surgery | ||||||
| Biopsy | 413 (16.0%) | 151 (23.3%) | 0.172 | 17.3% | 16.5% | 0.021 |
| Resection | 2069 (80.3%) | 470 (72.5%) | 0.174 | 78.9% | 79.7% | 0.021 |
| None | 95 (3.69%) | 27 (4.17%) | 0.024 | 3.8% | 3.8% | 0.003 |
| Time from diagnosis to index (months) | 3.56 | 4.56 | 0.002 | 3.74 | 3.61 | 0.0003 |
| Baseline daily dexamethasone dose (mg) | 3.49 | 5.21 | 0.342 | 3.83 | 3.99 | 0.034 |
| Radiation dose per fraction | ||||||
| 0 to 2 Gy | 67.7% | 54.5% | 0.266 | 65% | 64.1% | 0.018 |
| 2.1 to 3 Gy | 29.9% | 43.5% | 0.274 | 32.7% | 33.5% | 0.017 |
| 3.1 to 5 Gy | 1.4% | 1.5% | 0.012 | 1.4% | 1.5% | 0.003 |
| Unknown | 1% | < 6 | 0.075 | 0.9% | 0.9% | 0.005 |
Abs. SMD, absolute standardized mean difference.
aMean or N and proportion.